BofA lowered the firm’s price target on GoodRx (GDRX) to $4.25 from $4.50 and keeps an Underperform rating on the shares after the company ...

GoodRx (NASDAQ:GDRX – Free Report) had its price objective reduced by Citigroup from $7.00 to $6.25 in a research note issued ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

Citi analyst Daniel Grosslight lowered the firm’s price target on GoodRx (GDRX) to $6.25 from $7 and keeps a Buy rating on the shares as part ...

GoodRx Holdings, Inc. (NASDAQ:GDRX – Get Free Report) dropped 8.4% during trading on Monday after Citigroup lowered their price target on the stock from $7.00 to $6.25. Citigroup currently has a buy ...

Prices for insulin, the essential drug for treating diabetes, have plummetted to their lowest levels in a decade following a ...

Analysts have set 12-month price targets for GoodRx Holdings, revealing an average target of $6.25, a high estimate of $7.00, and a low estimate of $6.00. Highlighting a 26.47% decrease ...

The average price per insulin unit hit a 10-year low in 2024, largely driven by federal actions and voluntary price cuts from drugmakers, according to a Jan. 15 GoodRx report.

GoodRx (Nasdaq: GDRX), the leading prescription savings platform in the U.S., today announced a new GoodRx for Pets ...

Goodrx Holdings Inc (GDRX) stock saw a modest uptick, ending the day at $4.57 which represents a slight increase of $0.15 or 3.39% from the prior close of $4.42. The stock opened at $4.41 and touched ...